Abstract: Prenatal hypoxia predisposes the offspring to the development of cardiovascular (CV) dysfunction in adult life. Using a rat model, we assessed the effect of prenatal hypoxia on vasoconstrictive and vasodilative mechanisms in left anterior descending coronary arteries of 4- and 9.5-month-old offspring. Endothelium-dependent relaxation to methylcholine and vasoconstriction responses to endothelin-1 (ET-1) were assessed by wire myography. Prenatal hypoxia impaired endothelium-dependent vasodilation in 4- and 9.5-month-old offspring. Inhibition of nitric oxide (NO) synthase prevented coronary artery relaxation in all groups. Inhibition of prostaglandin H synthase (PGHS) improved relaxation in prenatally hypoxic males and tended to improve vasorelaxation in females, suggesting that impaired vasodilation was mediated via increased PGHS-dependent vasoconstriction. An enhanced contribution of endothelium-dependent hyperpolarization to coronary artery vasodilation was observed in prenatally hypoxic males and females. No changes in endothelial NO synthase (eNOS) and PGHS-1 expressions were observed, while PGHS-2 expression was decreased in only prenatally hypoxic males. At 4 months, ET-1 responses were similar between groups, while ETB inhibition (with BQ788) tended to decrease ET-1-mediated responses in only prenatally hypoxic females. At 9.5 months, ET-1-mediated responses were decreased in only prenatally hypoxic females. Our data suggest that prenatal hypoxia has long-term similar effects on the mechanisms of impaired endothelium-dependent vasodilation in coronary arteries from adult male and female offspring; however, coronary artery contractile capacity is impaired only in prenatally hypoxic females. Understanding the mechanistic pathways involved in the programming of CV disease may allow for the development of therapeutic interventions.

Keywords: pregnancy complications; prenatal hypoxia; cardiovascular dysfunction; developmental origins of health and disease (DOHaD); offspring; coronary artery function; endothelin-1 (ET-1); endothelial dysfunction; sex differences

1. Introduction

Pregnancy-related complications severely impact the health and lifespan of offspring [1]. Fetal hypoxia is a major consequence of complicated pregnancies that affects normal fetal development and can result in the restriction of fetal growth [2]. Previous research demonstrated that fetal hypoxia leads to changes in offspring cardiovascular (CV) function and predisposes the offspring to the development of CV dysfunction in later life [3-9]; however, the mechanisms remain to be fully elucidated.

Seminal research by Barker et al. demonstrated a strong association between disproportional (human) growth at birth and predisposition to the development of ischemic heart disease (IHD) [10]. In particular, a low birth weight, short birth length, small head circumference at birth, and low ponderal index were associated with increased risk of IHD and coronary heart disease (CHD) in adulthood [10,11], while an increase in birth
weight correlated with a proportional reduction in the rate of IHD and CHD [12,13]. In humans, complicated pregnancies have been associated with an enhanced coronary blood flow in the fetus and in neonates [14–16]. Moreover, previous research in various animal models of pregnancy complications reported left ventricular (LV) hypertrophy and an increased coronary artery vascular reactivity (in lambs [17] and fetal sheep [18]), decreased fetal LV capillarization (in fetal rabbit [19]) and total myocardial capillary length (in rat neonates [20]), increased passive coronary arterial stiffness (in lambs [21]), and substantial structural remodeling of coronary vascular tree (in fetal rabbit [22]). However, little is known regarding the long-term effects of complicated pregnancies on adult offspring coronary artery function. One study showed that prenatal cocaine exposure results in sex-dependent dysfunction of coronary autoregulation in adult offspring. For instance, prenatal cocaine exposure caused a decrease in coronary myogenic tone in male offspring, but resulted in increased coronary myogenic tone in the females [23]. Moreover, another study reported that prenatal hypoxia was associated with attenuated serotonin- and protein kinase C (PKC) agonist-mediated contractile responses in the coronary arteries of adult male offspring (female offspring were not assessed) [24]. Taking into account that coronary circulation is essential in maintaining proper cardiac performance and represents ~5% of total cardiac output [25], the dysfunction of coronary arteries has been attributed to the development of myocardial ischemia [26] and severe clinical outcomes.

The vascular endothelium plays a major role in maintaining vascular function and homeostasis. Primarily, the vascular endothelium is involved in the production and release of endothelium-derived relaxing factors (such as nitric oxide (NO), prostacyclin- PGI$_2$, and endothelium-derived hyperpolarization (EDH)), and endothelium-derived constricting factors (such as endothelin-1 (ET-1) and thromboxane A$_2$) [27]. An imbalance between vasodilation and vasoconstriction has been implicated in the development of endothelial dysfunction [28], resulting in CV dysfunction [29]. Previous reports suggest that offspring exposed to prenatal hypoxia are more prone to the development of hypertension [30], accompanied by an enhanced vasoconstrictor reactivity to big ET-1 (a precursor of ET-1) and an impaired NO-dependent endothelial function in the systemic circulation [4,30]. However, the link between prenatal hypoxia and coronary artery function in adult male and female offspring has not been fully explored. In the current study, we hypothesized that prenatal hypoxia impairs coronary artery function in adult offspring by reducing endothelium-dependent vasodilation and constrictor capacity in adult (4- and 9.5-month-old) male and female offspring.

2. Materials and Methods

2.1. Animal Model of Prenatal Hypoxia

Three-month-old female Sprague–Dawley rats (Charles River, Kingston, NY; Raleigh, NC; Hollister, CA, USA) were mated overnight by housing with 3-month-old Sprague–Dawley males. Pregnancy was confirmed the following morning by the presence of sperm in the vaginal smear (designated as gestational day [GD] 0). Throughout the pregnancy period, dams were single housed in standard rat cages under a 10:14 h light–dark cycle and fed standard rat chow ad libitum. Pregnant rats were randomly divided into two groups: normoxic controls (housed at atmospheric oxygen throughout pregnancy: 21% O$_2$; normoxia group) or hypoxic dams (exposed to hypoxia from GD 15–21 by placing them in a hypoxic chamber: 11% O$_2$; p-hypoxia group). The pregnant rats were removed from the hypoxic chamber on GD 21 (term = GD 22) and were allowed to give birth in standard housing and oxygen conditions. At birth, litter size was decreased to 8 pups/litter (4 males and 4 females) to standardize postnatal conditions. On postnatal day 21, offspring were weaned, separated by sex, and double housed in standard housing conditions until either 1) ~4 months or 2) ~9.5 months of age. At 4 or 9.5 months of age, offspring were anesthetized by inhaled isoflurane (pre-oxygenation with oxygen alone for 4–5 breaths, starting off with 0.5% isoflurane and increasing the isoflurane percentage by 0.5% increments every few breaths to a maximum of 4%). Hearts were immediately excised and placed in ice-cold
HEPES-buffered physiological saline solution (PSS; composition (in mmol/L): 10 HEPES, 5.5 glucose, 1.56 CaCl$_2$, 4.7 KCl, 142 NaCl, 1.18 MgSO$_4$, 1.18 KH$_2$PO$_4$, and pH 7.4) for assessment of ex vivo vascular function in the coronary arteries (see below). Plasma was collected using ethylenediaminetetraacetic acid (EDTA) anticoagulant, centrifuged, and stored at −80 °C for assessment of ET-1 levels. The main left coronary artery was isolated and immediately snap-frozen in optimal cutting temperature compound (Tissue-Tek®, Sakura Finetek, Torrance, CA, USA) for further molecular analysis.

### 2.2. Coronary Artery Vascular Function by Wire Myography

After collection of the heart, the left descending coronary artery (LADs; 150–250 µm) was isolated and cleaned from the myocardium in ice-cold PSS and divided into ~1–2 mm segments. Vascular function was assessed ex vivo using wire myography. The successful dissection and isolation of these vessels allowed us to obtain 1–3 segments of LAD per one heart. Subsequently, we used one to two offspring per one dam, in order to perform all the vascular function experiments (please see below). The data are presented based on the dam as the experimental unit; thus, duplicate (control) curves from 2 offspring from the same dam were averaged. The segments of LAD were mounted onto a wire myograph system (620M DMT, Copenhagen, Denmark) using 25 µm tungsten wires. Isometric tension of the vessels was recorded using LabChart software (version 8.1.13; AD Instruments; Colorado Springs, CO, USA). All vessels were normalized through a series of stepwise increases in diameter to reach their optimal resting tension: 0.8 × IC100; 13.3 kPa (the internal circumference equivalent to a transmural pressure of 100 mmHg). After normalization, the vessels were exposed to the first wake up dose of the thromboxane A$_2$ receptor agonist 9,11-Dideoxy-11α,9α-epoxymethanoprostaglandin F2α (U-46619; 1 µmol/L; Sigma-Aldrich, St. Louis, MO, United States) for 5 min. After washing with PSS thrice and 10 min rest, the vessels were exposed to a second wake up dose of U-46619, followed by a single dose of methylcholine (MCh; 3 µmol/L; Sigma-Aldrich), to confirm endothelial cell function. If LAD segments developed spontaneous sustained vasoconstriction during the experiment, the data obtained from those segments were excluded. After washing and 30 min of rest, vascular responses to MCh were assessed using a cumulative concentration response curve (CCRC; 0.001 µmol/L to 100 µmol/L MCh; doses were added in 2-min intervals) after pre-constriction with a pre-calculated EC$_{80}$ concentration of U-46619 (0.2 µmol/L; the mean effective concentration that produces 80% of the maximal response). After washing with PSS thrice and 30 min of rest, vasoconstriction responses to ET-1 were assessed in LAD of 4-month-old and 9.5-month-old offspring using CCRCs to ET-1 (CCRC; 0.0001 µmol/L to 0.3 µmol/L; Sigma-Aldrich) in the presence or absence of ET$_A$ (BQ-123; 10 µmol/L) or ET$_B$ (BQ-788; 10 µmol/L) receptor antagonists [31]. As we observed impaired vasodilation to MCh at 4-months, which was maintained at 9.5 months of age, specific vasodilation pathways potentially involved in the impaired endothelium-dependent vasodilation were assessed in the 9.5-month-old offspring. CCRCs to MCh were performed in the absence or presence (30 min pre-incubation prior to U-46619 EC$_{30}$ dose) of the following specific inhibitors: NO synthase (NOS) was inhibited with the pan NOS inhibitor N(G)-nitro-L-arginine methyl ester hydrochloride (L-NAME; 100 µmol/L; Sigma-Aldrich) [32], prostaglandin H synthase (PGHS) was inhibited with meclofenamate (10 µmol/L; Sigma-Aldrich), and EDH-mediated vasodilation was inhibited with a combination of apamin (0.5 µmol/L; Sigma-Aldrich) [33], which blocks small-conductance Ca$^{2+}$-activated potassium channels (SK) and 1-(2-chlorophenyl)diphenylmethyl-1H-pyrazole (Tram-34; 0.4 µmol/L; Sigma-Aldrich) [33], an intermediate-conductance Ca$^{2+}$-activated potassium channel (IK) inhibitor. Simultaneously, a CCRC to the NO donor sodium nitroprusside (SNP CCRC; 0.0001 µmol/L to 10 µmol/L, Sigma-Aldrich; doses were added in 2-min intervals) was conducted in one of the LAD segments to assess endothelium-independent relaxation. All data were presented as the maximum relaxation response to MCh ($F_{max}$), the negative log of the mean effective concentration that produces 20% and 50% of the maximal response (pEC$_{20}$ and pEC$_{50}$, respectively), as a measure of vasodilator sensitivity, or as area under the curve (AUC).
2.3. Molecular Assessment of Plasma ET-1 Levels with ELISA

Plasma levels of ET-1 were assessed using a rat endothelin-1 ELISA kit (Boster Bio, Pleasanton, CA, USA, Cat# EK0952), according to the manufacturer’s instructions. Briefly, on the day of experiment, plasma samples were thawed on ice and vortexed. All reagents and working standards of the ELISA kit were prepared on the same day as the assay procedure. After adding all standards, controls, and samples in duplicate, plates were sealed and incubated for 90 min at 37°C. The plates were emptied, and each well was washed with washing solution 3 times. Next, biotinylated anti-rat Edn1 antibody was added in each well, sealed, and incubated for 60 min at 37°C. Afterwards, the plates were emptied and washed 3 times with washing buffer. Avidin-biotin-peroxidase complex was added in each well, and the plate was sealed and incubated for 30 min at 37°C. Plates were emptied, and each well was washed with washing solution 5 times. Color developing reagent was added to each well, and plates were sealed and incubated in the dark for 20 min at 37°C. Stop solution was added, and the absorbance of each well was measured under 450 nm wavelength within 30 min with multimode reader (BioTek Synergy HTX, Santa Clara, CA, USA). To determine the amount of ET-1 in the plasma sample, a standard curve was generated by plotting the average absorbance (450 nm) obtained for each of the eight standard ET-1 concentrations provided. The absorbance value was calculated for each standard and sample well, and all absorbance values (average of duplicates) were subtracted by the average of the zero-standard value (i.e., the blank). The levels of ET-1 in each plasma sample were calculated using the standard curve.

2.4. Immunofluorescent Staining of the Main Left Coronary Artery for ET-1, ET<sub>A</sub>, ET<sub>B</sub>, eNOS, PGHS-1, and PGHS-2

Cryo-sections (9 µm) of coronary arteries of the 4- and 9.5-month-old offspring were prepared using a cryostat (SLEE medical GmbH, Nieder-Olm, Germany) for immunofluorescent detection of ET-1, endothelin A (ET<sub>A</sub>), and endothelin B (ET<sub>B</sub>) receptors, and for eNOS, PGHS-1, and PGHS-2 in coronary arteries of the 9.5-month-old offspring. Sections were fixed in ice cold methanol (−20°C for 10 min), then acetone (-20°C for 5 min), air-dried, and washed in phosphate buffer saline (PBS, pH: 7.5; 3 × 5 min). Afterwards, sections were subjected to an autofluorescence reduction treatment by incubating with NaBH<sub>4</sub> in PBS (1 mg/mL) for 10 min at room temperature (RT) and washed with PBS (3 × 10 min). After incubation with blocking solution (PBS supplemented with 2% donkey serum and 1% bovine serum albumin (BSA) with 0.1% Triton X-100 in PBS) for 1 h at room temperature, sections were washed with PBS (3 × 10 min) and incubated overnight at 4°C in 1% BSA/PBS with the primary antibodies. The primary antibodies used were as follows: ET-1 (1:50; rabbit polyclonal anti-ET-1, Bioss Cat# bs-0954R, RRID:AB_10855124, USA), ET<sub>A</sub> (1:300; rabbit polyclonal anti-ETA, Thermo Fisher Scientific, Waltham, MA; USA; Cat# PA3–065, RRID:AB_11153077), ET<sub>B</sub> (1:50; rabbit polyclonal anti-ETB, Bioss Cat# bs-4198R, RRID:AB_11076171), eNOS (1:50; mouse monoclonal anti-eNOS (NOS Type III), BD Biosciences, Mississauga, ON, Canada; Cat# 610297, AB_397691), PGHS-1 (1:100; rabbit polyclonal anti-COX-1, Abcam, Waltham, MA, USA; Cat# ab53766, RRID:AB_879753), PGHS-2 (1:50; rabbit polyclonal anti-COX-2, Abcam Cat# ab52237, RRID:AB_869240), or CD31 (1:200; mouse monoclonal anti-PECAM-1, BD Pharmingen, Mississauga, ON, Canada; Cat# 550300, RRID:AB_393595). The next day, sections were washed with PBS (3 × 5 min) and incubated with secondary antibodies (all at 1:250; Thermo Fisher Scientific) with 4′,6′-diamidino-2-phenylindole (DAPI; 1:500 Thermo Fisher Scientific Cat# D3571, RRID:AB_2307445) in 1% BSA/PBS for 1 h at RT in the dark: donkey-anti-mouse Alexa Fluor™ (Thermo Fisher Scientific) 488 (Cat # A-21202, RRID: AB_141607) for eNOS, donkey-anti-mouse Alexa Fluor™ 546 (Cat # A10036, RRID:AB_2534012) for CD31, and donkey-anti-rabbit Alexa Fluor™ 488 (Cat # A-21206, RRID:AB_2535792) for ET-1, ET<sub>A</sub>, ET<sub>B</sub>, PGHS-1, and PGHS-2. After washing in PBS (3 × 10 min), mounting medium containing DAPI was added (Vector Laboratories, Burlingame, CA, USA), and slides were stored in the dark and left to dry overnight. Immunofluorescent images were obtained the next
day using a confocal Zeiss LSM 700 microscope with Zen Black software (version 8.1.6.484; Zeiss, Toronto, ON, Canada). Gains for AF546, AF488, and DAPI were set using the blank sections (i.e., incubated with secondary antibody only).

2.5. Image Analysis of Immunofluorescence Staining

Fluorescent images of ET-1, ET\textsubscript{A}, ET\textsubscript{B}, eNOS, PGHS-1, and PGHS-2 staining in the coronary arteries were analyzed using FIJI ImageJ software (version 1.53n; Wayne Rasband NIH, Bethesda, MD, USA). The total vessel area was selected for ET-1, ET\textsubscript{A}, eNOS, PGHS-1, and PGHS-2, the vessel area outside of the endothelium (the area negative for CD31) was selected for ET\textsubscript{B} (ET\textsubscript{B} that are located on VSMCs mediate vasoconstriction [34]), and the mean fluorescent intensity was measured.

2.6. Statistical Analysis

Data from the dose response curves were fitted to the Hill equation, and pEC\textsubscript{50} and pEC\textsubscript{20} values were calculated. The pEC\textsubscript{50} and pEC\textsubscript{20} values are defined as the negative logarithm of the EC\textsubscript{50} and EC\textsubscript{20} (the concentration of agonist that provokes a response 50% and 20% of maximum response, respectively) and represent receptor sensitivity to the agonist. For methylcholine (in the presence or absence of L-NAME) and ET-1 (in the presence or absence of BQ123 or BQ788) dose response curves, the area under the curve (AUC) was calculated as a cumulative measurement of an inhibitor effect. Data were analyzed by student t-test or two-way ANOVA with Sidak’s post-hoc test (GraphPad Prism, version 9.1.2; San Diego, CA, USA; https://www.graphpad.com/scientific-software/prism/). Data were presented as means ± standard error of the mean (SEM); p < 0.05 was considered statistically significant.

3. Results

3.1. Coronary Artery Endothelium-Dependent and Endothelium-Independent Vasodilation Responses

3.1.1. Endothelium-Dependent Vasodilation Was Impaired in Prenatally Hypoxic Male and Female 4-Month-Old Offspring

MCh-induced vasodilation responses were decreased in p-hypoxia males, while the sensitivity to MCh was comparable between normoxia and p-hypoxia groups. In females, MCh-induced vasodilation responses and sensitivity to MCh tended to decrease in the p-hypoxia group, compared to normoxia control (Figure 1A,B). In contrast, no changes in the vascular responses to the NO donor (SNP) were observed in the coronary arteries of 4-month-old male (E\textsubscript{max}: normoxia: 98.95 ± 1.11 vs. p-hypoxia: 94.11 ± 1.51, n = 6–8 dams/group) or female offspring (E\textsubscript{max}: normoxia: 98.56 ± 0.79 vs. p-hypoxia: 96.83 ± 1.75, n = 6–8 dams/group).

3.1.2. Impaired Endothelium-Dependent Vasodilation in Prenatally Hypoxic Male and Female 9.5-Month-Old Offspring

With an advancement in age, at 9.5 months of age, maximal vasodilation responses to MCh and the sensitivity to MCh were decreased in the coronary arteries of p-hypoxia males and females (Figure 2A,B). SNP-mediated vasodilation responses were similar between normoxia and p-hypoxia males (E\textsubscript{max} normoxia: 100.02 ± 0.0.37 vs. p-hypoxia: 98.47 ± 1.37, n = 6–8 dams/group) and females (E\textsubscript{max} normoxia: 98.95 ± 0.66 vs. p-hypoxia: 97.73 ± 2.65, n = 6–8 dams/group).

3.2. Mechanisms of Endothelium-Dependent Vasodilation in Male and Female 9.5-Month-Old Offspring

Because an impairment in MCh-induced vasodilation was maintained at 9.5 months of age in both male and female offspring, specific vasodilation pathways potentially involved in the impaired endothelium-dependent vasodilation were assessed in the 9.5-month-old offspring.
3.2.1. The Nitric Oxide Synthase (NOS) Pathway Is a Major Contributor to Coronary Artery Endothelium-Dependent Vasodilation in Male and Female Offspring

Pre-incubation with L-NAME prevented MCh-induced vasorelaxation in normoxia and p-hypoxia male offspring (Figure 3A). Because eNOS is a predominant NOS isoform in the vasculature and is responsible for most of the NO produced, we assessed the eNOS protein expression in the coronary artery tissue of the offspring. The eNOS expression was similar between normoxia and p-hypoxia male offspring (Figure 3A). Similar to the male offspring, in the coronary arteries of female offspring, pre-incubation with L-NAME prevented MCh-induced vasorelaxation in the normoxia and p-hypoxia groups (\( p < 0.0001 \); Figure 3B). eNOS levels were similar between the normoxia and p-hypoxia groups (Figure 3B).

3.2.2. Enhanced Contribution of the PGHS Pathway to Coronary Artery Endothelium-Dependent Vasodilation in Prenatally Hypoxic Offspring

In the male offspring, pre-incubation with meclofenamate did not affect MCh-induced vasorelaxation in the normoxia group, while meclofenamate increased the max MCh-induced vasodilation in the p-hypoxia offspring. Since PGHS-1 and PGHS-2 are key enzymes involved in the conversion of arachidonic acid to prostaglandins (PGs) and other eicosanoids, coronary artery tissue expression of PGHS-1 and PGHS-2 was assessed. Coronary artery PGHS-1 expression was similar between the normoxia and p-hypoxia male offspring, while the expression of PGHS-2 was lower (\( p = 0.050 \)) in the p-hypoxia group, compared to the normoxia male offspring (Figure 4A). Similar to the male offspring, in females, pre-incubation with meclofenamate tended to increase (\( p = 0.06 \)) MCh-induced vasorelaxation in only the p-hypoxia offspring (Figure 4B). Coronary artery expressions of PGHS-1 and PGHS-2 were not different between the normoxia and p-hypoxia groups (Figure 4B).
Figure 2. Endothelium-dependent vasodilation in 9.5-month-old male (A) and female (B) offspring exposed to prenatal hypoxia. (i) Endothelium-dependent vasodilation responses to increasing doses of methylcholine (MCh) in left descending coronary arteries of Normoxia (red) and p-Hypoxia (blue) male (circles) and female (squares) 9.5-month-old offspring. (ii) Data were summarized as maximal vasodilation to MCh (E\textsubscript{max}) and (iii) the sensitivity to MCh (the negative logarithm of the EC\textsubscript{50}, pEC\textsubscript{50}), n = 7–10 dams/group. Data are presented as mean ± SEM; analyzed by t-test; * p < 0.05, ** p < 0.01.

3.2.3. The Contribution of Endothelium-Derived Hyperpolarization (EDH) to Endothelium-Dependent Vasodilation Is Enhanced in Coronary Arteries of Prenatally Hypoxia Male and Female Offspring

In the males, pre-incubation with apamin and Tram-34 decreased coronary artery sensitivity to MCh in the p-hypoxia group only (Figure 5A). In females, apamin and Tram-34 did not alter coronary artery sensitivity to MCh in normoxia group, while it decreased coronary artery sensitivity to MCh in the p-hypoxia offspring (Figure 5B).

3.3. Coronary Artery Responses to ET-1 and the Contribution of ET\textsubscript{A} and ET\textsubscript{B}

3.3.1. Increased Contribution of ET\textsubscript{B} Receptors to ET-1 Mediated Vasoconstriction in 4-Month-Old Female Offspring

In 4-months-old male offspring, ET-1-mediated coronary artery responses and ET-1 expression were similar between the normoxia and p-hypoxia groups (Figure 6A). Moreover, ET-1 plasma levels were comparable between normoxia and p-hypoxia males (normoxia: 1.40 ± 0.19 pg/mL vs. p-hypoxia: 1.13 ± 0.36 pg/mL, n = 6–7 dams/group).

BQ123 (a competitive antagonist of ET\textsubscript{A}) decreased the vasoconstriction responses to ET-1 to a similar extent in both the normoxia and p-hypoxia males (normoxia: 1.40 ± 0.19 pg/mL vs. p-hypoxia: 1.13 ± 0.36 pg/mL, n = 6–7 dams/group).

BQ123 (a competitive antagonist of ET\textsubscript{A}) decreased the vasoconstriction responses to ET-1 to a similar extent in both the normoxia and p-hypoxia males (normoxia: 1.40 ± 0.19 pg/mL vs. p-hypoxia: 1.13 ± 0.36 pg/mL, n = 6–7 dams/group).
Figure 3. Contribution of nitric oxide to coronary artery endothelium-dependent vasodilation in 9.5-month-old male and female offspring. (i) Endothelium-dependent vasodilation responses to increasing doses of methylcholine (MCh) in the presence or absence of L-NAME (NOS inhibitor N(G)-nitro-L-arginine methyl ester hydrochloride) in left descending coronary arteries of Normoxia (red) and p-Hypoxia (blue) male (A; circles) and female (B; squares) 9.5-month-old offspring. (ii) Data are summarized as area under the curve (AUC) in the absence or presence of L-NAME, n = 5–10 dams/group. (iii) Representative confocal images of immunofluorescence staining of eNOS (green) and quantitative analysis of eNOS expression in coronary arteries of Normoxia (red symbol) and p-Hypoxia (blue symbol) male (A; circles) and female (B; squares) 9.5-month-old offspring; n = 5–6 dams/group. Data are presented as mean ± SEM; analyzed by two-way ANOVA with Sidak’s multiple comparison post-hoc test or t-test, * p < 0.05, *** p < 0.001, **** p < 0.0001.
Figure 4. Contribution of the prostaglandin-H synthase (PGHS) pathway to endothelium-dependent vasodilation in 9.5-month-old male and female offspring. (a). (i) Endothelium-dependent vasodilation responses to increasing doses of methylcholine (MCh) in the presence or absence of meclofenamate (a PGHS inhibitor) in left descending coronary arteries of Normoxia (red) and p-Hypoxia (blue) male (A; circles) and female (B; squares) 9.5-month-old offspring. (ii) Data are summarized as maximum vasodilation response (Emax) in the absence or presence of meclofenamate; n = 4–10 dams/group. (b). (i,ii) Representative confocal images of PGHS-1 (green) and PGHS-2 (green) expression, and quantitative analysis of immunofluorescence staining for PGHS-1 and PGHS-2 in coronary arteries of Normoxia (red) and p-Hypoxia (blue) male (circles) and female (squares) offspring; n = 4–6 dams/group. Data are presented as mean ± SEM; analyzed by t-test or two-way ANOVA with Sidak’s multiple comparison post-hoc test, * p < 0.05, ** p < 0.01.
Figure 5. Contribution of endothelium-derived hyperpolarization to endothelium-dependent vasodilation in 9.5-month-old male and female offspring. (i) Endothelium-dependent vasodilation responses to increasing doses of methylcholine (MCh) in the presence or absence of apamin and Tram-34 (small- and intermediate-conductance Ca\textsuperscript{2+}-activated potassium channels inhibitors) in left descending coronary arteries of Normoxia (red) and p-Hypoxia (blue) male (A; circles) and female (B; squares) 9.5-month-old offspring. (ii) Data are summarized as the sensitivity to MCh (the negative logarithm of the EC\textsubscript{20}, pEC\textsubscript{20}; n = 5–9 dams/group). Discontinuous line for Figures 5Aii and 5Bii is used to better visualize the data. Data are presented as mean ± SEM; analyzed by two-way ANOVA with Sidak’s multiple comparison post-hoc test, * p < 0.05, ** p < 0.01.

In 4-month-old females, ET-1 mediated coronary artery constriction responses were similar between the normoxia and p-hypoxia groups (Figure 6B). The ET-1 expression was increased in the p-hypoxia females, compared to normoxia group (Figure 6B), while the plasma levels of ET-1 were similar between normoxia and p-hypoxia male offspring (normoxia: 4.65 ± 0.86 pg/mL vs. p-hypoxia: 4.11 ± 0.67 pg/mL, n = 7 dams/group). BQ123 decreased ET-1-mediated vasoconstriction in both the normoxia and p-hypoxia offspring, while no significant differences in ET\textsubscript{A} expression were observed between the groups (Figure 6B). BQ788 did not alter ET-1 mediated coronary artery responses in the normoxia offspring, while ET-1 mediated vasoconstriction tended to be decreased (p = 0.058) by BQ788 in the p-hypoxia offspring (Figure 6B). However, ET\textsubscript{B} expression was similar between the normoxia and p-hypoxia groups (Figure 6B).

3.3.2. An Impaired ET-1 Mediated Vasoconstriction in 9.5-Month-Old Female Offspring

In 9.5-month-old male offspring, ET-1 mediated coronary artery responses and coronary tissue expression of ET-1 were similar between the normoxia and p-hypoxia groups (Figure 7A). Plasma levels of ET-1 were similar between normoxia and p-hypoxia male offspring (normoxia: 4.65 ± 0.86 pg/mL vs. p-hypoxia: 4.11 ± 0.67 pg/mL, n = 7 dams/group). BQ123 (a competitive antagonist of ET\textsubscript{A}) decreased, to a similar extent, the vasoconstriction responses to ET-1 in both the normoxia and p-hypoxia males (Figure 7A). ET\textsubscript{A} expression was similar between normoxia and p-hypoxia males (Figure 7A). Pre-incubation with BQ788 (a selective ET\textsubscript{B} antagonist) did not alter ET-1 mediated coronary artery responsiveness in the normoxia and p-hypoxia males, and coronary expression of ET\textsubscript{B} was similar between normoxia and p-hypoxia groups (Figure 7A).
Figure 6. ET-1-mediated vasoconstriction, contribution of ET<sub>B</sub> to ET-1-mediated response and coronary tissue levels of ET-1 and ET<sub>B</sub> in 4-month-old male and female offspring. (i) ET-1-mediated vasoconstriction in the presence or absence of (a) BQ123 (a competitive antagonist of ET<sub>A</sub>) or (b) BQ788 (a selective ET<sub>B</sub> receptors antagonist) in left descending coronary arteries of Normoxia (red) and p-Hypoxia (blue) male (A; circles) and female (B; squares) 4-month-old offspring. (ii) Data are summarized as area under the curve (AUC); n = 4–9 dams/group. (c) Representative confocal images of (i) ET-1 (green), (ii) ET<sub>A</sub> (green) and (iii) ET<sub>B</sub> (green) co-stained with CD31 (endothelial cell marker; red) and quantitative analysis of immunofluorescence staining in Normoxia (red symbol) and p-Hypoxia (blue symbol) male (circles) and female (squares) offspring; n = 4–6 dams/group. Data are presented as mean ± SEM; analyzed by t-test or two-way ANOVA with Sidak’s multiple comparison post-hoc test, ** p < 0.01, **** p < 0.0001.
Figure 7. ET-1-mediated vasoconstriction, contribution of ET\textsubscript{B} to ET-1-mediated response and coronary tissue levels of ET-1 and ET\textsubscript{B} in 9.5-month-old male and female offspring. ET-1-mediated
vasoconstriction in the presence or absence of (a) BQ123 (a competitive antagonist of ET\textsubscript{A}) or (b) BQ788 (a selective ET\textsubscript{B} receptors antagonist) in left descending coronary arteries of Normoxia (red) and p-Hypoxia (blue) male (A; circles) and female (B; squares) 9.5-month-old offspring. (ii) Data are summarized as area under the curve (AUC); \( n \) = 5–8 dams/group. (c) Representative confocal images of (i) ET-1 (green), (ii) ET\textsubscript{A} (green), and (iii) ET\textsubscript{B} (green) co-stained with CD31 (endothelial cell marker; red) and quantitative analysis of immunofluorescence staining in Normoxia (red symbol) and p-Hypoxia (blue symbol) male (circles) and female (squares) offspring; \( n \) = 5–6 dams/group. Data are presented as mean ± SEM; analyzed by \( t \)-test or by two-way ANOVA with Sidak’s multiple comparison post-hoc test, * \( p < 0.05 \), ** \( p < 0.01 \), *** \( p < 0.001 \), **** \( p < 0.0001 \).

In female offspring, ET-1 mediated responses were reduced in the p-hypoxia group, compared to the normoxia controls (Figure 7B). The ET-1 tissue levels were similar between normoxia and p-hypoxia groups (Figure 7B), while the plasma levels tended to be lower in the p-hypoxia groups, compared to normoxia (normoxia: 10.47 ± 0.82 pg/mL vs. p-hypoxia: 7.67 ± 1.02 pg/mL; \( p = 0.065 \), \( n \) = 6–8 dams/group). Pre-incubation with BQ123 (a competitive antagonist of ET\textsubscript{A} receptors) decreased the vasoconstriction responses to ET-1 in the normoxia and p-hypoxia females, while the coronary tissue levels of ET\textsubscript{A} were similar between the normoxia and p-hypoxia groups (Figure 7B). Pre-incubation with BQ788 (a selective ET\textsubscript{B} antagonist) did not alter the ET-1-mediated coronary artery responsiveness in the normoxia and p-hypoxia females, and coronary expression of ET\textsubscript{B} was similar between normoxia and p-hypoxia groups (Figure 7B).

4. Discussion

In the current study, we demonstrated that hypoxia, experienced during prenatal life, is associated with changes in the vasoconstrictor and vasodilator capacity of coronary arteries in adult male and female offspring. We showed that prenatal hypoxia impairs endothelium-dependent vasodilation in both males and females at 4- and 9.5-month of age. Nitric oxide was the predominant vasodilatory pathway in coronary circulation. However, in both males and females exposed to prenatal hypoxia, the impaired endothelium-dependent vasodilation appeared to be mediated via enhanced prostaglandin H-synthase-dependent vasoconstriction. Moreover, a higher contribution of endothelium-dependent hyperpolarization to coronary artery vasodilation was observed in prenatally hypoxic males and females. In 4-month-old offspring, prenatal hypoxia did not affect ET-1-mediated responsiveness, but tended to increase the contribution of ET\textsubscript{B} to ET-1 vasoconstriction in female offspring only. With advancement in age, vasoconstriction responses of the coronary arteries to ET-1 were reduced by prenatal hypoxia in only the female offspring, without effects of prenatal hypoxia on ET\textsubscript{B}-mediated responses in either sex.

4.1. The Effect of Prenatal Hypoxia on Coronary Artery Endothelium-Dependent and Endothelium-Independent Vasodilation in Adult Male and Female Offspring

To the best of our knowledge, we showed, for the first time, that prenatal exposure to hypoxia impairs endothelium-dependent vasodilation in coronary arteries of male and female offspring at 4 and 9.5 months of age. The coronary endothelium regulates vascular tone by releasing vasoconstricting and vasodilating factors, and an impairment in endothelium-dependent vasodilation has been shown to contribute to the development of various CV pathophysiological states [35], such as hypertension [36], atherosclerotic vascular disease [37], and congestive heart failure [38]. We, and others, have previously reported an impaired cardiac tolerance to ischemia/reperfusion (I/R) injury in the offspring exposed to prenatal hypoxia [39–42]. As impaired vasodilation of the coronary microcirculation has been associated with defects in myocardial perfusion (suggestive of myocardial ischemia) [43], it may be speculated that the impaired functional properties of the coronary arteries, observed in the current study, are a significant contributor factor to the development of cardiac dysfunction of adult offspring.

Further assessment of the potential mechanisms of the impaired endothelium-dependent vasodilation in the 9.5-month-old offspring revealed that, in the LAD, endothelium-
dependent vasodilation is predominantly mediated via NO, which has been previously reported in large epicardial coronary arteries [44,45]. NO is produced in the tissue by conversion of L-arginine to L-citrulline by NOS [46]. eNOS is critical for normal vascular homeostasis and is responsible for generating endothelial-derived NO [47]. Previous studies reported that coronary artery endothelial dysfunction may be associated with an increase [48], as well as decrease [49,50], in eNOS expression. In the current study, however, we did not observe any changes in eNOS expression in either males or females due to prenatal hypoxia.

Interestingly, in 9.5-month-old adult male and female offspring, we observed that inhibition of PGHS improved the impairment in MCh-induced vasorelaxation induced by prenatal hypoxia. PGHS is an enzyme involved in the production of PGs, which include vasodilator (PGI\textsubscript{2}; prostacyclin), as well as the vasoconstrictor, compounds (prostaglandin H\textsubscript{2}, prostaglandin F\textsubscript{2α} and TXA\textsubscript{2}). PGs are critical modulators of vascular tone in both physiological and pathophysiological conditions (reviewed by [51,52]). Because the inhibition of PGHS improved MCh-induced vasorelaxation in prenatally hypoxia males and females, PGHS expression was assessed in the coronary artery tissue. Prenatal hypoxia did not alter PGHS-1 and PGHS-2 expression in females and PGHS-1 expression in males, which suggests that not the levels but the activity of the PGHS pathway involved in the production and action of constrictive PGs or TXA\textsubscript{2} may be enhanced by prenatal hypoxia, thereby contributing to an impaired vasodilation. In contrast to the females, the expression of PGHS-2 was decreased in the prenatally hypoxic male offspring. Although PGHS-2 expression and activity is enhanced in various pathophysiological conditions, such as preeclampsia, hypertension, and ageing (reviewed in [51]), previous research demonstrated an essential role of PGHS-2 in postnatal CV maturation (the transition of the cardiopulmonary circulation at birth) [53] and in the maintenance of normal renal architecture (progression of the renal dysplasia seen in COX (PGHS)-2–deficient mice) [54], and PGHS-2 downregulation has been shown to contribute to the development of kidney pathologies, due to intrauterine growth restriction [55]. Thus, it may be suggested that a lower expression of PGHS-2 in the coronary arteries of the adult male offspring may be an indication of an early-life adaptation of the coronary circulation to adverse intrauterine environment during pregnancies complicated with prenatal hypoxia.

We observed that, in normoxic and prenatally hypoxic male and female offspring, endothelial hyperpolarization through SK\textsubscript{Ca} and IK\textsubscript{Ca} channels appears to contribute to endothelium-dependent vasodilation. Both the SK\textsubscript{Ca} and IK\textsubscript{Ca} channels play an important channel-specific role in the endothelium-dependent vasodilation (reviewed by [56,57]). For instance, SK\textsubscript{Ca} are mainly expressed in caveolae and are important for the activation of NOS, while IK\textsubscript{Ca} can be mainly found within myoendothelial gap junction-associated endothelial cell projections [58]. SK\textsubscript{Ca} and IK\textsubscript{Ca} channel activation generates an endothelium-dependent hyperpolarization that is conducted along the endothelium and into the smooth muscle cell layer, leading to smooth muscle cell hyperpolarization and subsequent inhibition of vascular tone [59]. An impaired function of SK\textsubscript{Ca} and IK\textsubscript{Ca} channels has been observed in various CV pathologies [60,61]. Moreover, it has been reported that hypoxia, per se, leads to a reduction in the expression level of SK\textsubscript{Ca} and IK\textsubscript{Ca}, as well as a reduction in endothelial K\textsuperscript{+} currents via SK\textsubscript{Ca} and IK\textsubscript{Ca} channels in porcine coronary arteries (in either sex) [62]. Thus, it may be suggested that the EDH pathway is maintained in prenatally hypoxic males and females as an additional mechanism to compensate for an impaired relaxation capacity of coronary arteries, thus maintaining coronary artery vasorelaxation in males and females.

4.2. The Effect of Prenatal Hypoxia on Coronary Artery ET-1 System in Male and Female Offspring

At 4 months of age, ET-1 tissue levels were increased in coronary arteries from prenatal hypoxia females only, while ET-1-mediated vasoconstriction and plasma levels of ET-1 were not affected by prenatal hypoxia in either sex. Previous research in an adult rat model of chronic intermittent hypoxia reported an enhanced ET-1 expression in coronary vessels
that was accompanied with an enhanced ET-1-mediated response [63]. Thus, it can be suggested that prenatal hypoxia may have an adaptive response in that, although there was an increase in ET-1 expression, this was not accompanied by an increased ET-1-mediated coronary artery responsiveness.

The biological effects of ET-1 are achieved via activation of the ET_A and ET_B [34]. In the vasculature, ET_B are located on the endothelium and VSMCs. The upregulation of ET_B on VSMCs is often observed in atherosclerosis [64] and ischemic heart disease [65], as their activation potentiates ET-1-mediated vasoconstriction. On the VSMCs, ET_B activation induces the activation of phospholipase C-β, which results in the increase in inositol 1,4,5-trisphosphate and diacylglycerol (DAG). DAG activates PKC, which phosphorylates the actin-binding protein calponin or leads to phosphorylation of caldesmon, thereby increasing the myofilament force sensitivity to Ca^{2+}, resulting in constriction [34]. Additionally, previous research has demonstrated a sex-specific function of ET_B [66]. Thus, in men, the activation of ET_B mediates tonic vasoconstriction in the blood vessels of the skin, while in females, it results in tonic vasodilation in the same type of blood vessels [66]. We demonstrated that, in 4-month-old prenatally hypoxic male offspring, the inhibition of ET_B receptors did not alter ET-1-mediated vasoconstriction, while in prenatal hypoxic female offspring, ET_B inhibition tended to decrease ET-1-mediated vasoconstriction. In a rat model of prenatal hypoxia, Chen et al. previously showed an attenuated constriction of coronary arteries of male (5-month-old; females were not assessed) offspring, which was associated with a decreased PKCβ² Ser660 phosphorylation [24]. However, as our functional results were not associated with changes in ET_B expression, and it may be speculated that it is the downstream signaling of ET_B receptors that was impacted by prenatal hypoxia in female offspring, which resulted in sex-specific changes in an ET_B-dependent functional response.

In 9.5-month-old offspring, prenatal hypoxia decreased ET-mediated coronary artery responsiveness in female offspring and tended to decrease the plasma levels of ET-1 (likely due to reduced ET-1 release or an enhanced ET-1 clearance from the circulation). While the long-term effect of prenatal hypoxia on the coronary artery ET-1 system is currently unknown, a decreased ET-1-mediated vasoconstriction in coronary arteries has been previously reported in obese rats, and this was associated with the uncoupling of [Ca^{2+}]; signaling, while ET-1, ET_A, and ET_B expressions were not changed [67]. Moreover, a reduction in ET-1-induced coronary artery contraction has been observed in deoxycorticosterone acetate (DOCA)-salt hypertensive rats, which was associated with the uncoupling of ET-1-receptors and impaired [Ca^{2+}]; signaling [68]. Thus, it may be that the reduction in ET-1-mediated vasoconstriction in 9.5-month-old females is attributed to impaired [Ca^{2+}]; signaling; however, further studies are warranted.

5. Conclusions

In the current study, we showed that prenatal hypoxia has long-term and sex-specific effects on the mechanisms of coronary artery vasodilation and vasoconstriction. As coronary artery function is essential in maintaining cardiac performance, coronary artery dysfunction may contribute to the development of cardiac dysfunction and an impaired cardiac tolerance to I/R insult in adult offspring that has been previously reported [39,41,42]. Understanding the mechanistic pathways involved in the programming of CV disease allows for the development of future prenatal and postnatal therapeutic interventions.

Author Contributions: Conceptualization, N.H., F.S., C.-L.M.C. and S.T.D.; methodology, N.H., R.L., F.S., M.P., A.Q., R.K. and S.T.D.; formal analysis, N.H; investigation, N.H and R.L.; data curation, N.H., F.S., and S.T.D.; writing—original draft preparation, N.H., F.S. and S.T.D.; writing—review and editing, N.H., R.L., F.S., M.P., A.Q., R.K., C.-L.M.C. and S.T.D.; visualization, N.H.; supervision, F.S. and S.T.D.; project administration, N.H; funding acquisition, N.H., C.-L.M.C. and S.T.D. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by a foundation grant from the Canadian Institutes of Health Research (FS154313) and by the Women and Children’s Health Research Institute (WCHRI) through the generosity of the Stollery Children’s Hospital Foundation and the Alberta Women’s Health Foundation. S.D. is a former Tier 1 Canada Research Chair in Maternal and Perinatal Cardiovascular Health and a Distinguished University Professor at the University of Alberta. N.H. was supported by a Stefan and Pelagia Wychowanec Graduate Scholarship and a Motyl Graduate Studentship in Cardiac Sciences from the University of Alberta. M.P. was supported by a WCHRI Graduate Studentship award and Faculty of Medicine and Dentistry 75th Anniversary Award from the University of Alberta.

Institutional Review Board Statement: The animal study protocol was approved on November 26, 2020 by the Animal Care and Use Committee Health Sciences 2 (Animal Policy and Welfare Committee of the University of Alberta), in accordance with the Canadian Council on Animal Care and the “Guide for the Care and Use of Laboratory Animals” (AUP #3692).

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available, due to privacy.

Acknowledgments: None.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Cheong, J.N.; Wlodek, M.E.; Moritz, K.M.; Cuffe, J.S. Programming of maternal and offspring disease: Impact of growth restriction, fetal sex and transmission across generations. J. Physiol. 2016, 594, 4727–4740. [CrossRef] [PubMed]
2. Thompson, L.P.; Crimmins, S.; Telugu, B.; Turan, S. Intrauterine hypoxia: Clinical consequences and therapeutic perspectives. Res. Rep. Neonatol. 2015, 5, 79–89. [CrossRef]
3. Giussani, D.A.; Davidge, S.T. Developmental programming of cardiovascular disease by prenatal hypoxia. J. Dev. Orig. Health Dis. 2013, 4, 328–337. [CrossRef]
4. Bourque, S.L.; Gragasin, F.S.; Quon, A.L.; Mansour, Y.; Morton, J.S.; Davidge, S.T. Prenatal hypoxia causes long-term alterations in vascular endothelin-1 function in aged male, but not female, offspring. Hypertension 2013, 62, 753–758. [CrossRef] [PubMed]
5. Ream, M.; Ray, A.M.; Chandra, R.; Chikaraishi, D.M. Early fetal hypoxia leads to growth restriction and myocardial thinning. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 295, R583–R595. [CrossRef]
6. Chen, X.; Zhang, L.; Wang, C. Prenatal hypoxia-induced epigenomic and transcriptomic reprogramming in rat fetal and adult offspring hearts. Sci. Data 2019, 6, 238. [CrossRef] [PubMed]
7. Crispi, F.; Miranda, J.; Gratacos, E. Long-term cardiovascular consequences of fetal growth restriction: Biology, clinical implications, and opportunities for prevention of adult disease. Am. J. Obstet Gynecol. 2018, 218, S869–S879. [CrossRef] [PubMed]
8. Giussani, D.A.; Camm, E.J.; Niu, Y.; Richter, H.G.; Blanco, C.E.; Gottschalk, R.; Blake, E.Z.; Horder, K.A.; Thakor, A.S.; Hansell, J.A.; et al. Developmental programming of cardiovascular dysfunction by prenatal hypoxia and oxidative stress. PLoS ONE 2012, 7, e31017. [CrossRef]
9. Zhang, L. Prenatal hypoxia and cardiac programming. J. Soc. Gynecol. Investig. 2005, 12, 2–13. [CrossRef]
10. Barker, D.J.; Winter, P.D.; Osmond, C.; Margetts, B.; Simmonds, S.J. Weight in infancy and death from ischaemic heart disease. Lancet 1989, 2, 577–580. [CrossRef]
11. Stein, C.E.; Fall, C.H.; Kumaran, K.; Osmond, C.; Cox, V.; Barker, D.J. Fetal growth and coronary heart disease in south India. Lancet 1996, 348, 1269–1273. [CrossRef] [PubMed]
12. Forsen, T.; Eriksson, J.G.; Tuomilehto, J.; Osmond, C.; Barker, D.J. Growth in utero and during childhood among women who develop coronary heart disease: Longitudinal study. BMJ 1999, 319, 1403–1407. [CrossRef] [PubMed]
13. Leon, D.A.; Lithell, H.O.; Vagero, D.; Koupilova, I.; Mohsen, R.; Berglund, L.; Lithell, U.B.; McKeigue, P.M. Reduced fetal growth rate and increased risk of death from ischaemic heart disease: Cohort study of 15 000 Swedish men and women born 1915-29. BMJ 1996, 317, 241–245. [CrossRef]
14. Aburawi, E.H.; Malec, P.; Thuring, A.; Fellman, V.; Pesonen, E. Coronary flow in neonates with impaired intrauterine growth. J. Am. Soc. Echocardiogr. 2012, 25, 313–318. [CrossRef]
15. Baschat, A.A.; Gemburc, U.; Harman, C.R. Coronary blood flow in fetuses with intrauterine growth restriction. J. Perinat Med. 1998, 26, 143–156.
16. Baschat, A.A.; Gemburc, U.; Reiss, I.; Gortner, L.; Diedrich, K. Demonstration of fetal coronary blood flow by Doppler ultrasound in relation to arterial and venous flow velocity waveforms and perinatal outcome—the ‘heart-sparing effect’. Ultrasound Obstet. Gynecol. 1997, 9, 162–172. [CrossRef] [PubMed]
17. Cleal, J.K.; Poore, K.R.; Boullin, J.P.; Khan, O.; Chau, R.; Hambidge, O.; Torrens, C.; Newman, J.P.; Poston, L.; Noakes, D.E.; et al. Mismatched pre- and postnatal nutrition leads to cardiovascular dysfunction and altered renal function in adulthood. Proc. Natl. Acad. Sci. USA 2007, 104, 9529–9533. [CrossRef]
18. Bubb, K.J.; Cock, M.L.; Black, M.J.; Dedic, M.; Boon, W.M.; Parkington, H.C.; Harding, R.; Tare, M. Intrauterine growth restriction delays cardiomyocyte maturation and alters coronary artery function in the fetal sheep. *J. Physiol.* 2007, 578, 871–881. [CrossRef]

19. Schipke, J.; Gonzalez-Tendero, A.; Cornejo, L.; Willfuhr, A.; Bijnens, B.; Crispi, F.; Muhlfield, C.; Gratacos, E. Experimentally induced intrauterine growth restriction in rabbits leads to differential remodelling of left versus right ventricular myocardial microstructure. *Histochem. Cell Biol.* 2017, 148, 557–567. [CrossRef]

20. Sutherland, M.R.; Ng, K.W.; Drenckhahn, J.D.; Wlodek, M.E.; Black, M.J. Impact of Intrauterine Growth Restriction on the Capillarization of the Early Postnatal Rat Heart. *Anat. Rec. (Hoboken)* 2019, 302, 1580–1586. [CrossRef]

21. Tare, M.; Parkington, H.C.; Wallace, E.M.; Sutherland, A.E.; Lim, R.; Yawno, T.; Coleman, H.A.; Jenkin, G.; Miller, S.L. Maternal melatonin administration mitigates coronary stiffness and endothelial dysfunction, and improves heart resilience to insult in growth restricted lambs. *J. Physiol.* 2014, 592, 2695–2709. [CrossRef] [PubMed]

22. Garcia-Canadilla, P.; de Vries, T.; Gonzalez-Tendero, A.; Bonnin, A.; Gratacos, E.; Crispi, F.; Bijnens, B.; Zhang, C. Structural coronary artery remodelling in the rabbit fetus as a result of intrauterine growth restriction. *PLoS ONE* 2019, 14, e0218192. [CrossRef] [PubMed]

23. Xue, Q.; Zhang, L. Prenatal hypoxia causes a sex-dependent increase in heart susceptibility to ischemia and reperfusion injury in adult male offspring. *Diabetes Res. Clin. Pract.* 2017, 126, 70–77. [CrossRef] [PubMed]

24. Chen, X.; Qi, L.; Su, H.; He, Y.; Li, N.; Gao, Q.; Li, H.; Xu, T.; Lu, L.; Xu, Z.; et al. Prenatal hypoxia attenuated contraction of offspring coronary artery associated with decreased PKCbeta Ser(660) phosphorylation and intracellular calcium. *Life Sci.* 2020, 261, 118364. [CrossRef]

25. Deussen, A.; Ohanyan, V.; Jannasch, A.; Yin, L.; Chilian, W. Mechanisms of metabolic coronary flow regulation. *Biomedicines* 2020, 9, 17. [CrossRef]

26. Radico, F.; Zimarino, M.; Fulgenzi, F.; Ricci, F.; Di Nicola, M.; Jespersen, L.; Chang, S.M.; Humphries, K.H.; Marzilli, M.; De Caterina, R. Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: A systematic review and meta-analysis. *Eur. Heart J.* 2018, 39, 2135–2146. [CrossRef] [PubMed]

27. Sandoo, A.; van Zanten, J.J.; Metios, G.S.; Carroll, D.; Kitas, G.D. The endothelium and its role in regulating vascular tone. *Open Cardiovasc. Med. J.* 2010, 4, 302–312. [CrossRef]

28. Grover-Paez, F.; Zavalza-Gomez, A.B. Endothelial dysfunction and cardiovascular risk factors. *Diabetes Res. Clin. Pract.* 2009, 84, 1–10. [CrossRef]

29. Brain, K.L.; Allison, B.J.; Niu, Y.; Cross, C.M.; Itani, N.; Kane, A.D.; Herrera, E.A.; Skeffington, K.J.; Giussani, D.A. Intervention against hypertension in the next generation programmed by developmental hypoxia. *PLoS Biol.* 2019, 17, e2006552. [CrossRef]

30. Chen, X.; Qi, L.; Su, H.; He, Y.; Li, N.; Gao, Q.; Li, H.; Xu, T.; Lu, L.; Xu, Z.; et al. Prenatal hypoxia attenuated contraction of offspring coronary artery associated with decreased PKCbeta Ser(660) phosphorylation and intracellular calcium. *Life Sci.* 2020, 261, 118364. [CrossRef] [PubMed]

31. Garcia-Villalon, A.L.; Fernandez, N.; Monge, L.; Salcedo, A.; Dieguez, G. Effects of endothelin-1 on the relaxation of rat coronary arteries. *J. Mol. Cell Cardiol* 2012, 52, 794–801. [CrossRef]

32. Climent, B.; Moreno, L.; Martinez, P.; Contreras, C.; Sanchez, A.; Perez-Vizcaino, F.; Garcia-Sacristan, A.; Rivera, L.; Prieto, D. Upregulation of SK3 and IK1 channels contributes to the enhanced endothelial calcium signaling and the preserved coronary relaxation in obese Zucker rats. *PLoS ONE* 2019, 4, e109432. [CrossRef] [PubMed]

33. Mazzuca, M.Q.; Khalil, R.A. Vascular endothelin receptor type B: Structure, function and dysregulation in vascular disease. *PLoS Biol.* 2012, 10, 147–162. [CrossRef] [PubMed]

34. Grover-Paez, F.; Zavalza-Gomez, A.B. Endothelial dysfunction and cardiovascular risk factors. *Diabetes Res. Clin. Pract.* 2009, 84, 1–10. [CrossRef]

35. Lerman, A.; Burnett, J.C., Jr. Intact and altered endothelium in regulation of vasomotion. *Circulation* 1992, 86, III12–III19.

36. Panza, J.A.; Quyyumi, A.A.; Brush, J.E., Jr.; Epstein, S.E. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. *N. Engl. J. Med.* 1990, 323, 22–27. [CrossRef]

37. Vila, J.A.; Treasure, C.B.; Nabel, E.G.; McLenachan, J.M.; Fish, R.D.; Yeung, A.C.; Vekstein, V.I.; Selwyn, A.P.; Ganz, P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. *Circulation* 1990, 81, 491–497. [CrossRef]

38. Climent, B.; Moreno, L.; Martinez, P.; Contreras, C.; Sanchez, A.; Perez-Vizcaino, F.; Garcia-Sacristan, A.; Rivera, L.; Prieto, D. Upregulation of SK3 and IK1 channels contributes to the enhanced endothelial calcium signaling and the preserved coronary relaxation in obese Zucker rats. *PLoS ONE* 2019, 4, e109432. [CrossRef] [PubMed]

39. Mazzuca, M.Q.; Khalil, R.A. Vascular endothelin receptor type B: Structure, function and dysregulation in vascular disease. *Front. Physiol.* 2012, 3, 147–162. [CrossRef] [PubMed]

40. Panza, J.A.; Quyyumi, A.A.; Brush, J.E., Jr.; Epstein, S.E. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. *N. Engl. J. Med.* 1990, 323, 22–27. [CrossRef]

41. Vila, J.A.; Treasure, C.B.; Nabel, E.G.; McLenachan, J.M.; Fish, R.D.; Yeung, A.C.; Vekstein, V.I.; Selwyn, A.P.; Ganz, P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. *Circulation* 1990, 81, 491–497. [CrossRef]

42. Chong, A.Y.; Freestone, B.; Patel, J.; Lim, H.S.; Hughes, E.; Blann, A.D.; Lip, G.Y. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. *Am. J. Cardiol.* 2006, 97, 671–675. [CrossRef]

43. Niu, Y.; Kane, A.D.; Lushy, C.M.; Allison, B.J.; Chua, Y.Y.; Kaandorp, J.J.; Nevin-Dolan, R.; Ashmore, T.J.; Blackmore, H.L.; Derks, J.B.; et al. Maternal Allopurinol Prevents Cardiac Dysfunction in Adult Male Offspring Programmed by Chronic Hypoxia During Pregnancy. *Hypertension* 2018, 72, 971–978. [CrossRef]

44. Rueda-Clausen, C.F.; Morton, J.S.; Davidge, S.T. Effects of hypoxia-induced intrauterine growth restriction on cardiopulmonary structure and function during adulthood. *Cardiovasc. Res.* 2009, 81, 713–722. [CrossRef]

45. Xu, Y.; Williams, S.J.; O’Brien, D.; Davidge, S.T. Hypoxia or nutrient restriction during pregnancy in rats leads to progressive cardiac remodeling and impairs posts ischemic recovery in adult male offspring. *FASEB J.* 2006, 20, 1251–1253. [CrossRef] [PubMed]

46. Hasdai, D.; Gibbons, R.J.; Holmes, D.R., Jr.; Higano, S.T.; Lerman, A. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. *Circulation* 1997, 96, 3390–3395. [CrossRef] [PubMed]
44. Quyyumi, A.A.; Dakak, N.; Andrews, N.P.; Hussein, S.; Arora, S.; Gilligan, D.M.; Panza, J.A.; Cannon, R.O., 3rd. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J. Clin. Invest. 1995, 95, 1747–1755. [CrossRef] [PubMed]

45. Kellin, M.; Schrader, J. Control of coronary vascular tone by nitric oxide. Circ. Res. 1990, 66, 1561–1575. [CrossRef] [PubMed]

46. Levine, A.B.; Puniaholeo, D.; Levine, T.B. Characterization of the role of nitric oxide and its clinical applications. Cardiology 2012, 122, 55–68. [CrossRef]

47. Garcia, V.; Sessa, W.C. Endothelial NOS: Perspective and recent developments. Br. J. Pharmacol 2019, 176, 189–196. [CrossRef]

48. Berges, A.; Van Nassauw, L.; Timmermans, J.P.; Vrints, C. Role of nitric oxide during coronary endothelial dysfunction after myocardial infarction. Eur. J. Pharmacol. 2005, 516, 60–70. [CrossRef]

49. Chen, C.; Ochoa, L.N.; Kagan, A.; Chai, H.; Liang, Z.; Lin, P.H.; Yao, Q. Lysophosphatidic acid causes endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Atherosclerosis 2012, 222, 74–83. [CrossRef]

50. Ramaswami, G.; Chai, H.; Yao, Q.; Lin, P.H.; Lumsden, A.B.; Chen, C. Curcumin blocks homocysteine-induced endothelial dysfunction in porcine coronary arteries. J. Vasc Surg. 2004, 40, 1216–1222. [CrossRef]

51. Davidge, S.T. Prostaglandin H synthase and vascular function. Circ. Res. 2006, 98, 1059–1064. [CrossRef] [PubMed]

52. Goodwill, A.G.; Dick, G.M.; Kiel, A.M.; Tune, J.D. Regulation of Coronary Blood Flow. Compr. Physiol. 2017, 7, 321–382. [CrossRef] [PubMed]

53. Loftin, C.D.; Trivedi, D.B.; Tiano, H.F.; Clark, J.A.; Lee, C.A.; Epstein, J.A.; Morham, S.G.; Breyer, M.D.; Nguyen, M.; Hawkins, B.M.; et al. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc. Natl. Acad. Sci. USA 2001, 98, 1059–1064. [CrossRef] [PubMed]

54. Norwood, V.F.; Morham, S.G.; Smithies, O. Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice. Kidney Int. 2000, 58, 2291–2300. [CrossRef] [PubMed]

55. Baserga, M.; Hale, M.A.; Wang, Z.M.; Yu, X.; Callaway, C.W.; McKnight, R.A.; Lane, R.H. Uteroplacental insufficiency alters nphosphogenes and downregulates cyclooxygenase-2 expression in a model of IUGR with adult-onset hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292, R1943–R1955. [CrossRef] [PubMed]

56. Ellinsworth, D.C.; Sandow, S.L.; Shukla, N.; Liu, Y.; Jeremy, J.Y.; Gutterman, D.D. Endothelium-Derived Hyperpolarization and Coronary Vasodilation: Diverse and Integrated Roles of Epoxyeicosatrienoic Acids, Hydrogen Peroxide, and Gap Junctions. Microcirculation 2016, 23, 15–32. [CrossRef]

57. Edwards, G.; Feletou, M.; Weston, A.H. Endothelium-derived hyperpolarising factors and associated pathways: A synopsis. Pflugers Arch. 2010, 459, 863–879. [CrossRef]

58. Sandow, S.L.; Neylon, C.B.; Chen, M.X.; Garland, C.J. Spatial separation of endothelial small- and intermediate-conductance calcium-activated potassium channels (K(Ca)) and connexins: Possible relationship to vasodilator function? J. Anat. 2006, 209, 689–698. [CrossRef]

59. Socha, M.J.; Behringer, E.J.; Segal, S.S. Calcium and electrical signalling along endothelium of the resistance vasculature. Basic Clin. Pharmacol. Toxicol. 2012, 110, 80–86. [CrossRef]

60. Gracic, I.; Kaistha, B.P.; Hoyer, J.; Kohler, R. Endothelial Ca++-activated K+ channels in normal and impaired EDHF-dilator responses–relevance to cardiovascular disease and drug discovery. Br. J. Pharmacol. 2009, 157, 509–526. [CrossRef]

61. Fung, J.; Liu, Y.; Clements, R.T.; Sodha, N.R.; Khabbaz, K.R.; Senthinathan, V.; Nishimura, K.K.; Alper, S.L.; Sellke, F.W. Calcium-activated potassium channels contribute to human coronary microvascular dysfunction after cardiopulmonary arrest. Circulation 2008, 118, S46–S51. [CrossRef] [PubMed]

62. Yang, Q.; Huang, J.H.; Man, Y.B.; Yao, X.Q.; He, G.W. Use of intermediate/small conductance calcium-activated potassium-channel activator for endothelial protection. J. Thorac. Cardiovasc. Surg. 2012, 111, 501–510.e1. [CrossRef] [PubMed]

63. Wang, J.W.; Li, A.Y.; Guo, Q.H.; Guo, Y.J.; Weiss, J.W.; Ji, E.S. Endothelin-1 and ET receptors impair left ventricular function by mediated coronary arteries dysfunction in chronic intermittent hypoxia rats. Physiol. Rep. 2017, 5. [CrossRef] [PubMed]

64. Dagassan, P.H.; Breu, V.; Clozel, M.; Kunzli, A.; Vogt, P.; Turina, M.; Kiowski, W.; Clozel, J.P. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J. Cardiovasc. Pharmacol. 1996, 27, 147–153. [CrossRef]

65. Vackenfors, A.; Emilson, M.; Ingemansson, R.; Hortobagyi, T.; Szok, D.; Tajti, J.; Vecsei, L.; Edvinsson, L.; Malmstro, M. Ischemic heart disease induces upregulation of endothelin receptor mRNA in human coronary arteries. Eur. J. Pharmacol. 2004, 484, 103–109. [CrossRef]

66. Kellogg, D.L., Jr.; Liu, Y.; Pergola, P.E. Selected contribution: Gender differences in the endothelin-B receptor contribution to basal cutaneous vascular tone in humans. J. Appl. Physiol. (1985) 2001, 91, 2407–2411; discussion 2389–2490. [CrossRef]

67. Katakam, P.V.; Snipes, J.A.; Tulbert, C.D.; Mayanagi, K.; Miller, A.W.; Busija, D.W. Impaired endothelin-induced vasoconstriction in coronary arteries of Zucker obese rats is associated with uncoupling of [Ca(2+)]i signaling. Am. J. Physiol. Regul. Integr. Comp. Physiol 2006, 290, R145–R153. [CrossRef]

68. Giulianum, A.D.; Molero, M.M.; Reddy, V.B.; Pollock, J.S.; Pollock, D.M.; Fuchs, L.C. Role of ET-1 receptor binding and [Ca(2+)]i in contraction of coronary arteries from DOCA-salt hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 2002, 282, H1944–H1949. [CrossRef]